AGP expands Pharma portfolio with STADA Tie-Up, Xanax marketing deal

April 30, 2026 (MLN): AGP Limited (PSX: AGP) has outlined a multi-pronged growth strategy alongside new product commercialization agreements, pointing to an expansion in both its core pharmaceutical and consumer healthcare segments, according to filings with the Pakistan Stock Exchange (PSX).

At a board meeting held on April 29, the company authorized management to pursue strategic growth opportunities, including potential acquisitions, investments, and business combinations.

The initiative also covers internal optimization efforts aimed at improving operational efficiency and extracting synergies across AGP and its associated entities.

To advance this mandate, AGP will carry out feasibility, commercial, and valuation analyses to formulate proposals for board consideration.

The company may also engage legal, financial, and other advisors to support the process, indicating a structured approach toward potential expansion transactions.

Contract Marketing for Xanax

In a separate development, the board approved an arrangement with an associated company under which AGP will undertake contract marketing services for Xanax in Pakistan.

Under the proposed structure, AGP will hold commercialization and promotion rights for the product in the local market.

The launch is targeted for May 2026, subject to completion of regulatory and contractual formalities.

The move reflects a broader industry trend toward asset-light growth via marketing alliances.

STADA Partnership to Bring Oilatum Range

Additionally, AGP has agreed with STADA Arzneimittel AG, a global drugmaker with a presence in over 100 countries.

The agreement grants AGP marketing and distribution rights for the Oilatum range in Pakistan.

Oilatum, positioned in specialized skincare, is expected to strengthen AGP’s footprint in the consumer healthcare segment, where demand has been steadily rising.

The product range is also slated for launch in May 2026, pending completion of regulatory and contractual requirements.

The latest developments highlight AGP’s dual focus on near-term revenue generation through product launches and longer-term growth through strategic initiatives. 

Copyright Mettis Link News